SPHK2

Across TCGA pan-cancer cohorts, SPHK2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPHK2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SPHK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPHK2 expression acts as an unfavorable survival marker.

OV, ESCA, and UCEC are the cancer types where SPHK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
ESCA	OS	Median	All	0.268	0.707	.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	OS	Median	All	0.426	0.786	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPHK2–OV (OS)

Open the OV breakdown →